Elizabeth Howard - 01 Feb 2023 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role: EVP, GC, Compliance
Signature: /s/ David C. Hastings as attorney-in-fact for Elizabeth Howard
Issuer symbol: ABUS
Transactions as of: 01 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2023, 15:10:11 UTC
Previous filing: 20 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABUS	Common Shares	Award	$0	+69,700	+427%	$0.000000	86,024	01 Feb 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+278,700		$0.000000	278,700	01 Feb 2023	Common Shares	278,700	$2.90	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2	Includes 16,324 common shares acquired pursuant to the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan.
F3	This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.